IL-2 immune complexes (IL-2C), composed of IL-2 and the anti-IL-2 monoclonal antibody JES6-1, have been shown to selectively expand Tregs without broadly activating effector cells, with demonstrated therapeutic efficacy in asthma (104), acute lung injury (105), and COPD (106). Here, IL2 is linked to injury.